New England Journal of Medicine· 2018Q1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- 3,767citations
- Q1SCImago
- 2018year
Short summary
Adding atezolizumab to bevacizumab plus chemotherapy (ABCP) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic nonsquamous NSCLC compared to bevacizumab plus chemotherapy (BCP). Median PFS was 8.3 months for ABCP vs. 6.8 months for BCP (HR 0.62, P<0.001), and median OS was 19.2 months vs. 14.7 months (HR 0.78, P=0.02).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine